Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the efficacy (how well the drug works) of
ofatumumab and lenalidomide in patients with lymphoma and to investigate if any possible
unwanted side effects may occur. The purpose of the Phase I portion of this trial will be to
determine the maximum dose of these medications that can be given with minimal side effects.